Literature DB >> 15801951

The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.

Corey Casper1.   

Abstract

Fifty years ago, Dr Benjamin Castleman first described the unusual lymphoproliferative disorder that now bears his name. Over the subsequent decades, astute clinical and pathologic observations coupled with clever molecular biologic research have increased our understanding of the aetiology of Castleman disease (CD). This article proposes three broad CD variants based on both distinctive histopathology and clinical behaviour. The pivotal roles of infection with human herpesvirus 8 and interleukin-6 production in the development of CD are emphasized. Finally, the natural history of CD and the myriad of therapeutic options are reviewed in the context of a unified model of CD pathophysiology, and continued areas of uncertainty are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801951     DOI: 10.1111/j.1365-2141.2004.05311.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  89 in total

1.  Incidental finding of Castleman's disease in an asymptomatic young adult.

Authors:  Ibrahim Shahbuddin; Damian McKeon
Journal:  BMJ Case Rep       Date:  2009-12-09

2.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  Multicentric Castleman's disease with renal amyloidosis and mesangial proliferative glomerulonephritis: a case report.

Authors:  Zhicheng Tan; Lihua Wang; Chen Wang; Lifang Gao; Yanrong Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

Review 5.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

6.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

Review 7.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

8.  Anemia resolved by thoracoscopic resection of a mediastinal mass: a case report of unicentric Castleman's disease.

Authors:  Jong Hui Suh; Sook Hee Hong; Seong Cheol Jeong; Chan Beom Park; Kuk Bin Choi; Ok Ran Shin; Si Young Choi
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

9.  Unicentric Castleman Disease: An Unusual Cause of An Isolated Neck Mass.

Authors:  Anjay Kumar; Krittika Aggarwal; Himanshu Agrawal; Sonal Sharma; Pankaj Kumar Garg
Journal:  Malays J Med Sci       Date:  2016-06-30

10.  Optic neuropathy associated with Castleman disease.

Authors:  Ungsoo Kim; Jeong-Min Hwang
Journal:  Korean J Ophthalmol       Date:  2010-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.